By Nigam Arora & Dr. Natasha Arora
Signal(s) to enter, add, reduce, exit, hold or change.
GE Healthcare stock (GEHC) was bought at an average price of $56.30 not that long ago. It is trading at $77.24 as of this writing. There are nice profits in a short time.
Spinoffs Are Often Profitable
Spinoffs from large corporations are often profitable. Here are the reasons why spinoffs are often profitable:
- Top management gets totally focused on the unit that is spun off.
- The unit that gets spun off often gets more market opportunities as some companies who might not have done business with this unit previously due to conflicts with the prior parent corporation now become clients.
- The spun off unit often has more financial flexibility compared to when it was part of a big corporation.
- Top management is incentivized to run up the stock of the spinoff.
- It is easier for analysts to understand the business of the spinoff as it is simpler compared to the parent corporation. This often leads to buy recommendations.
GE Spinoff
Months ago, when General Electric (GE) decided that it was going to spin off its healthcare unit, The Arora Report had an eye on the spinoff to give a buy signal. When GE Healthcare started trading on a when issued basis, The Arora Report gave a buy signal on Dec. 30, 2022. Spinoffs often start trading on a when issued basis before the actual stock trading starts.
The Attraction
GE is known for its imaging solutions such as CT scanners, MRI scanners, mammography scanners, X-rays, ultrasound scanners, molecular scanners, and bone scanners.
It is a slow-growing solid business, but the attraction was that it was valued at a discount relative to its competitors.
The Reason To Take Partial Profits
The stock has run up very quickly. Now the discount has narrowed. Our very long term target that was given along with the buy zone was $88 – $110. The very long term target still remains the same, but due to the quick run-up, there is merit to taking partial profits right here. Also, consider raising the stop zone to $66.43 – $67.38 on the remaining position.
What To Do Now
Those in the stock may follow the parameters given above. Those not in the stock may consider waiting for a new signal.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
